Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ICAAC In Brief

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Noxafil graft vs. host data: Schering-Plough plans to submit an NDA for use of its novel triazole antifungal Noxafil (posaconazole) for prevention of invasive fungal infections (IFIs) in high-risk patients, the company says. One of the pivotals, presented at the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in Washington, D.C. Dec. 16-19, shows significantly greater efficacy in preventing aspergillosis compared to fluconazole. In the 600-patient trial of stem cell transplant recipients with graft-versus-host disease, seven Noxafil-treated patients (2%) developed aspergillosis compared to 21 for fluconazole (7%) (p=0.006). The study poster notes that Noxafil was "as effective" as fluconazole in preventing IFIs other than aspergillosis. A total of 16 Noxafil patients (5%) developed IFI of any kind compared to 27 in the fluconazole group (9%) (p=0.07). Noxafil has been "approvable" since June for refractory invasive fungal infections (1Pharmaceutical Approvals Monthly July 2005, In Brief)...

You may also be interested in...



Telavancin positive Phase III data

Theravance announces positive results from its pivotal Phase III ATLAS I and ATLAS II trials to assess the safety and efficacy of telavancin, an injectable lipoglycopeptide antibiotic for treatment of complicated skin and skin structure infections. The multi-center, multinational, double-blind studies enrolled 1,867 patients, 719 of whom were infected with methicillin-resistant Staphylococcus aureus. Both studies reached their primary endpoints of non-inferiority and achieved a numerically better clinical cure rate than vancomycin. The company announced Phase II results at the Interscience Conference on Antimicrobial Agents and Chemotherapy last December 1(Pharmaceutical Approvals Monthly January 2006, p. 36)...

Theravance telavancin pivotal enrollment complete

Theravance wraps up accrual in initial Phase III program evaluating its lipoglycopeptide antibiotic telavancin for use in complicated skin and skin structure infections due to Gram-positive bacteria, the San Francisco-based firm says May 16. "We have enrolled more than 1,800 patients overall and expect to have more than one-third with confirmed [methicillin-resistant Staphylococcus aureus] infections at baseline," the company says, noting that the design allows for detection of potential superiority over vancomycin, the standard treatment for MRSA infections. Phase II telavancin data were presented at the Interscience Conference on Antimicrobial Agents & Chemotherapy in Washington, D.C. in December. Cure rates for MRSA were similar for telavancin and standard care (1Pharmaceutical Approvals Monthly January 2006, p. 36)...

Schering-Plough Noxafil "approvable"

Schering-Plough plans to respond to FDA's request for additional data "as soon as possible" following the agency's June 10 "approvable" letter for the oral triazole antifungal Noxafil (posaconazole). Noxafil's user fee date for treatment of refractory invasive fungal infections fell in March, but Schering previously said the agency extended the review timeframe for an undisclosed length of time. The firm had been projecting a first-half 2005 decision...

Related Content

Topics

UsernamePublicRestriction

Register

OM017175

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel